Supercharge Your Innovation With Domain-Expert AI Agents!

Compounds for treating central nervous system degenerative diseases and their applications

A degenerative disease and central nervous system technology, applied in the field of medicine, can solve problems such as single target and lipoic acid instability

Active Publication Date: 2018-07-10
SUN YAT SEN UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, lipoic acid is unstable in the body, and its target is relatively single, and it only has antioxidant effect. In recent years, it has been used in combination with other drugs or as a pharmacophore for designing multi-target drugs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds for treating central nervous system degenerative diseases and their applications
  • Compounds for treating central nervous system degenerative diseases and their applications
  • Compounds for treating central nervous system degenerative diseases and their applications

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1 - 5-(1,2-dithiocyclopent-3-yl)-N-(4-(pyridin-4-yl)phenyl)pentanamide (1)

[0043]

[0044] Compound 1 was synthesized according to the above-mentioned synthetic route 1 to obtain a light yellow solid with a total yield of 52% in three steps. 1 H NMR (400 MHz, CDCl 3 ) δ 8.62 (d, J = 4.7 Hz, 2H), 7.96 (s, 1H), 7.68 (d, J = 8.1Hz, 2H), 7.60 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 5.2 Hz, 2H), 3.64 – 3.49 (m,1H), 3.22 – 3.04 (m, 2H), 2.53 – 2.33 (m, 3H), 1.90 (dt, J = 19.7, 6.8 Hz,1H), 1.84 – 1.62 (m, 4H), 1.61 – 1.43 (m, 2H). 13 C NMR (100 MHz, CDCl 3 ) δ171.4, 150.1, 147.7, 139.2, 133.4, 127.6, 121.3, 120.2, 56.4, 40.3, 38.5,37.4, 34.7, 28.9, 25.2. ESI-HRMS for [C 19 h 23 N 2 OS 2 ] + , calcd: 359.1246; found: 359.1232. Purity: 100% (HPLC). .

Embodiment 2

[0045] Example 2 - [5-(1,2-dithiocyclopentane-3-yl)-N-(2-fluoro-4-(pyridin-4-yl)phenyl)pentanamide (2)

[0046]

[0047] Compound 2 was synthesized according to the above-mentioned synthetic route 1 to obtain a light yellow solid, and the total yield of 3 steps was 32.8%. 1 H NMR (400 MHz, CDCl 3 ) δ 8.65 (d, J = 6.0 Hz, 2H), 8.48 (t, J = 8.2 Hz, 1H), 7.51 –7.35 (m, 5H), 3.66 – 3.53 (m, 1H), 3.25 – 3.06 (m, 2H), 2.57 – 2.37 (m, 3H),1.93 (td, J = 13.6, 6.9 Hz, 1H), 1.87 – 1.72 (m, 4H), 1.62 – 1.47 (m, 2H). 13 CNMR (100 MHz, CDCl 3 ) δ 170.16 (s), 151.50 (d, J = 243.8 Hz), 149.33 (s), 145.51 (d, J = 1.8 Hz), 133.04 (d, J = 7.5 Hz), 126.22 (d, J = 10.5 Hz), 122.13 (d, J = 3.0 Hz), 121.10 (s), 120.13 (s), 112.21 (d, J = 20.7 Hz), 55.32 (s), 39.24 (s), 37.49 (s), 36.43 (s), 33.64 (s), 27.80 (s), 24.07 (s). ESI-HRMS for [C 19 h 22 FN 2 OS 2 ] + ,calcd: 377.1158; found: 377.1151. Purity: 99% (HPLC).

Embodiment 3

[0048] Example 3 - 5-(1,2-dithiocyclopent-3-yl)-N-(2-methoxy-4-(pyridin-4-yl)phenyl)pentanamide (3)

[0049]

[0050] Compound 3 was synthesized according to the above-mentioned synthetic route 1 to obtain a light yellow solid, and the total yield of the three steps was 22%. 1 H NMR (400 MHz, CDCl 3 ) δ 8.62 (dd, J = 4.5, 1.6 Hz, 2H), 8.50 (d, J = 8.4 Hz, 1H),7.83 (s, 1H), 7.47 (dd, J = 4.5, 1.6 Hz, 2H), 7.29 – 7.23 (m, 1H), 7.11 (d, J= 1.8 Hz, 1H), 3.97 (s, 3H), 3.64 – 3.52 (m, 1H), 3.24 – 3.06 (m, 2H), 2.54 –2.39 (m , 3H), 1.97 – 1.85 (m, 2H), 1.83 – 1.69 (m, 4H), 1.60 – 1.47 (m, 2H). 13 C NMR (100MHz, CDCl 3 ) δ 170.0, 149.2, 147.1, 147.0, 132.3, 127.7, 120.3, 119.0, 107.3, 75.7, 55.4, 54.9, 39.3, 37.5, 36.7, 33.7, 27.8, 24.2. + ,calcd: 389.1352; found: 389.1350. Purity: 99%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to compounds for treating degenerative disease of a central nervous system, pharmaceutical composition and an application of the compounds. The compounds have a structure shown in a formula (I) and can be used as a ROCK inhibitor, and appropriate pharmaceutical dosage forms prepared from the compounds are used for treating the neurodegenerative disease.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to compounds, pharmaceutical compositions and applications for treating degenerative diseases of the central nervous system. The present invention also relates to a series of preparation methods and applications of multifunctional ROCK inhibitors, which can be made into appropriate pharmaceutical dosage forms for treating neurodegenerative diseases. Background technique [0002] The pathogenesis of central nervous system degenerative diseases (including Alzheimer's disease, Parkinson's disease, Huntington's disease, etc.) has not been fully elucidated, but it is generally believed that these diseases are caused by multiple factors, mainly including various signal transduction pathways oxidative stress and free radical formation, neuroexcitotoxicity and inflammatory responses, protein misfolding, dopaminergic and choline neurotransmitter imbalances, etc. This multifactorial contribution makes ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D409/12C07D409/14A61K31/4545A61K31/4436A61K31/4155A61K31/454A61P25/28A61P25/16A61P25/14A61P21/00
CPCC07D409/12C07D409/14
Inventor 皮荣标涂亚林文石军王胜男杨晓红陈秋荷陈景考
Owner SUN YAT SEN UNIV
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com